Bristol-Myers Squibb stock heads into the open after a 0.8% gain
Published on 09/21/2026 at 06:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, rising 0.8 percent from the prior session. The shares moved in a daily range between USD 62.19 and USD 63.06, with the closing price matching the session high. In the same session, the S&P 500 index gained 0.17 percent, so Bristol-Myers Squibb outperformed the broader benchmark on September 18, 2026.
September 18, 2026 in numbers
Bristol-Myers Squibb Co. (ISIN US1078421011, NYSE: BMY) recorded a close at USD 63.06 on the New York Stock Exchange on September 18, 2026, after trading between a low of USD 62.19 and a high of USD 63.06 during the session, with the high identical to the closing level. Per closing data for Bristol-Myers Squibb as of September 18, 2026, the session volume reached 36,576,219 shares, indicating active trading compared with typical recent turnover. According to a market wrap of United States equities for September 18, 2026, the S&P 500 index finished that day up 0.17 percent at 7,650.50 points, while the Dow Jones Industrial Average slipped 0.18 percent and the Nasdaq Composite added 0.39 percent, framing Bristol-Myers Squibb’s 0.8 percent rise against a mixed but generally constructive equity backdrop, as reported by Eastmoney.
Today’s backdrop and upcoming catalysts
Today, September 21, 2026, Bristol-Myers Squibb does not have a widely flagged company-specific event such as an earnings release or annual meeting that is dated within the next few trading days in major public calendars, so the shares head into the open primarily with the recent price performance and sector sentiment as context. However, the broader market tone following the quarterly options expiration and index rebalancing on September 18, 2026, described as a so-called triple witching day for United States markets by Eastmoney, could continue to influence large-cap health care names, including Bristol-Myers Squibb, as investors adjust positions heading into the coming weeks.
